Sugi Predict

Sugi Predict / Compounds / SCHEMBL5182292

SCHEMBL5182292

SCHEMBL5182292

NC(=O)CCC(NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ MDM4 O15151 3/20 0.56
▸ TP53 P04637 3/20 0.56
▸ TLR2 O60603 2/20 0.55
▸ MDM2 Q00987 6/20 0.52
▸ KMT2A Q03164 2/20 0.51
▸ CASP3 P42574 2/20 0.51
▸ SLC17A5 Q9NRA2 1/20 0.49
▸ PTPN1 P18031 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL800090 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL119475 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL29352431 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL29908079 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL29682425 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL29401101 1.00 MDM4 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL27435787 0.94 MDM2 (0.56) MDM4TP53TLR2MDM2KMT2A
SCHEMBL29694496 0.93 PTPN1 (0.58) MDM4TP53TLR2MDM2KMT2A
SCHEMBL30929979 0.92 TLR2 (0.49) MDM4TP53TLR2MDM2KMT2A
SCHEMBL30255589 0.92 TLR2 (0.49) MDM4TP53TLR2MDM2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 — — US disclosed
US-12077555-B2 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-03 — — US disclosed
CN-118146313-A Self-assembled short peptide and application thereof in hemostasis and injury repair 成都赛恩贝外科学研究院 2024-06-07 — — CN disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-10-19 — — US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 — — US disclosed
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-16 — — US disclosed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
US-20230026277-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE MICROX CO., LTD. (KR) 2023-01-26 — — US disclosed
WO-2020206424-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-10-08 — — WO disclosed
WO-2014033466-A1 METHOD AND COMPOSITIONS FOR REMOVING ACID-LABILE PROTECTING GROUPS STETSENKO DMITRY (GB) 2014-03-06 — — WO disclosed
EP-2452695-A2 Positron emission tomography imaging method Purdue Research Foundation (US) 2012-05-16 — — EP disclosed
EP-1797110-A1 ANTIBACTERIAL AMIDE MACROCYCLES IV AiCuris GmbH & Co. KG (DE) 2007-06-20 — — EP disclosed
US-20060275213-A1 Tumor targeting agents and uses thereof KARYON OY (FI) 2006-12-07 — — US disclosed
WO-2006034786-A1 ANTIBACTERIAL AMIDE MACROCYCLES IV AICURIS GMBH & CO.KG (DE) 2006-04-06 — — WO disclosed
CN-1720258-A Tumor targeting agents and uses thereof KARYON OY (FI) 2006-01-11 — — CN disclosed
EP-1549669-A1 TUMOR TARGETING AGENTS AND USES THEREOF Karyon OY (FI) 2005-07-06 — — EP disclosed
WO-2004031221-A9 TUMOR TARGETING AGENTS AND USES THEREOF KARYON OY (FI) 2004-07-08 — — WO disclosed
WO-2004031221-A1 TUMOR TARGETING AGENTS AND USES THEREOF KARYON OY (FI) 2004-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-20230026277-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE RELA, CSNK2A1, CSNK1G1 MDM4 3536/4885TP53 2055/4885TLR2 241/4885
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-12077555-B2 STAT degraders and uses thereof STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 MDM4 2467/4885TP53 2372/4885TLR2 3729/4885
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-20060275213-A1 Tumor targeting agents and uses thereof CCL2, CCL5, SCTR MDM4 901/4885TP53 46/4885TLR2 2715/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 MDM4 156/4885TP53 32/4885TLR2 1185/4885
US-20230330254-A1 ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF GLP1R, GIPR, GCGR MDM4 4805/4885TP53 4176/4885TLR2 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.